QLGN | tickerfilter.com

Fundamental analysis

18%

Profitability 0%

Dept financing 50%

Liquidity 55%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.56%

1 Month

-8.16%

3 Months

-19.15%

6 Months

1,768.47%

1 Year

650.80%

2 Year

195.15%

Key data

Stock price

$3.04

P/E Ratio

0.00

DAY RANGE

$2.96 - $3.05

EPS

-$3.24

52 WEEK RANGE

$0.08 - $5.14

52 WEEK CHANGE

$669.62

MARKET CAP

2.280 M

YIELD

N/A

SHARES OUTSTANDING

12.156 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

3.61

PUBLIC FLOAT

AVERAGE 10 VOLUME

$8,121

AVERAGE 30 VOLUME

$12,727

Company detail

CEO: Michael S. Poirier
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.

QLGN - Qualigen Therapeutics, Inc.